Gyermekkori daganatok: vizsgálatok itt: Izrael
35 of 43 trials · From ClinicalTrials.gov, checked 2026. november 19.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleBelzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- Where
- Ramat Gan, Tel Aviv
- Életkor
- 12 év and over
- People
- 355 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04924075 · EU 2023-504853-11-00 - 1/2. fázisTaking peopleSafety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
- Where
- Ramat Gan
- Életkor
- 1 év to 30 év
- People
- 50 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07387926 - 2/3. fázisTaking peopleA Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
- Where
- Haifa, Jerusalem, Ramat Gan, Tel Aviv
- Életkor
- 12 év and over
- People
- 340 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07570173 · EU 2025-522267-15-00 - 1/2. fázisTaking peopleA Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
- Where
- Haifa, Jerusalem, Ramat Gan, Tel Aviv
- Életkor
- 2 év and over
- People
- 420 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT04811560 · EU 2023-506581-31-00 - 2/3. fázisTaking peopleLong-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
- Where
- Beersheba, Jerusalem, Tel Aviv, Tel-Hashomer
- People
- 1541 worldwide
- Run by
- Celgene
See details and how to joinNCT03435796 · EU 2023-504201-36-00 - 1/2. fázisTaking peopleSubstudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Where
- Haifa, Ramat Gan
- Életkor
- 6 hónap to 25 év
- People
- 90 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00 - 1/2. fázisTaking peopleA Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
- Where
- Haifa, Petah Tikva, Ramat Gan
- Életkor
- 1 hónap to 17 év
- People
- 134 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07630974 · EU 2025-522339-32-00 - 3. fázisNot yet taking people in IzraelInternational Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
- Where
- Tel Aviv
- Életkor
- 1 év to 64 év
- People
- 750 worldwide
- Run by
- Charite University, Berlin, Germany
See details and how to joinNCT07476729 · EU 2023-509392-17-00 - 3. fázisTaking peopleStudy of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
- Where
- Haifa, Jerusalem, Petah Tikva, Tel Aviv, Tel HaShomer
- Életkor
- 12 év and over
- People
- 468 worldwide
- Run by
- Syndax Pharmaceuticals
See details and how to joinNCT07211958 · EU 2025-522279-27-00 - 3. fázisTaking peopleInterfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
- Where
- Petah Tikva
- Életkor
- 1 nap to 1 év
- People
- 160 worldwide
- Run by
- Princess Maxima Center for Pediatric Oncology
See details and how to joinNCT05327894 · EU 2022-502503-30-00 - 1/2. fázisTaking peopleA Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Where
- Haifa, Jerusalem, Nahariya, Petah Tikva, Ramat Gan
- Életkor
- 30 nap and over
- People
- 447 worldwide
- Run by
- Syndax Pharmaceuticals
See details and how to joinNCT04065399 · EU 2024-513759-34-00 - 2/3. fázisTaking peopleSafety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
- Where
- Beersheba, Petah Tikva, Ramat Gan, Tel Aviv
- Életkor
- 18 év and over
- People
- 740 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT06697301 · EU 2024-512659-19-00 - 1/2. fázisTaking peopleA Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
- Where
- Haifa, Ramat Gan
- Életkor
- 1 hónap to 17 év
- People
- 50 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06941272 · EU 2024-518771-66-00 - 1/2. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)
- Where
- Jerusalem, Tel Aviv
- People
- 64 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07602777 - 2. fázisTaking peopleA Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
- Where
- Haifa, Petah Tikva, Ramat Gan, Tel Aviv
- Életkor
- 1 év to 17 év
- People
- 100 worldwide
- Run by
- Pfizer
See details and how to joinNCT05748171 · EU 2023-509810-13-00 - 2. fázisTaking peoplePatients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5
- Where
- Jerusalem
- Életkor
- 12 hónap to 21 év
- People
- 10
- Run by
- Shaare Zedek Medical Center
See details and how to joinNCT07537400 - 2/3. fázisFut, nem toborozAllogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
- Where
- Haifa, Petah Tikva, Tel Aviv
- Életkor
- 1 hónap to 18 év
- People
- 1800 worldwide
- Run by
- St. Anna Kinderkrebsforschung
See details and how to joinNCT01949129 · EU 2024-512657-24-00 - 2. fázisTaking peopleA Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
- Where
- Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
- Életkor
- 12 év and over
- People
- 100 worldwide
- Run by
- AbbVie
See details and how to joinNCT07196644 · EU 2024-518871-74-00 - 2. fázisTaking peopleCombination Therapy for the Treatment of Diffuse Midline Gliomas
- Where
- Jerusalem, Tel HaShomer
- Életkor
- 2 év to 39 év
- People
- 360 worldwide
- Run by
- University of California, San Francisco
See details and how to joinNCT05009992 · EU 2023-507598-16-00 - 3. fázisNot yet taking people in IzraelInternational Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
- Where
- Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
- Életkor
- Up to 18 év
- People
- 683 worldwide
- Run by
- University Hospital Muenster
See details and how to joinNCT04043494 · EU 2023-508101-24-00 - 3. fázisTaking peopleONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
- Where
- Beersheba, Haifa, Jerusalem, Petah Tikva, Petah Tikvah, Ramat Gan, Tel Aviv
- People
- 510 worldwide
- Run by
- Jazz Pharmaceuticals
See details and how to joinNCT05580562 · EU 2022-502051-56-00 - 1/2. fázisNot yet taking people in IzraelA Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies
- Where
- Ramat Gan
- Életkor
- 1 év to 80 év
- People
- 50
- Run by
- Sheba Medical Center
See details and how to joinNCT07503353 - 2. fázisTaking peopleInternational Study for Treatment of High Risk Childhood Relapsed ALL 2010
- Where
- Tel Aviv
- Életkor
- Up to 17 év
- People
- 250 worldwide
- Run by
- Charite University, Berlin, Germany
See details and how to joinNCT03590171 · EU 2024-513070-21-00 - 1/2. fázisTaking peopleA Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies
- Where
- Ramat Gan
- Életkor
- 1 év to 80 év
- People
- 50
- Run by
- Sheba Medical Center
See details and how to joinNCT07135466 - 1/2. fázisTaking peopleModified Vaccine for High Risk or Low Residual Melanoma Patients
- Where
- Jerusalem
- People
- 50
- Run by
- Hadassah Medical Organization
See details and how to joinNCT01898039